(1)
Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial
ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of the Phase 1 clinical trial of camidanlumab tesirine (Cami), an anti-CD25 ADC, in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphomas have been published online in
The Lancet Haematology There is a significant unmet medical need for novel therapies that improve outcomes in patients with relapsed or refractory Hodgkin lymphoma, said Mehdi Hamadani, MD, Professor of Internal Medicine at the Medical College of Wisconsin, Division of Hematology Oncology and lead author of
To the Editor:
Sema K. Sgaier outlines the four different “personas” of vaccine-hesitant Americans, arguing that to address reluctance, “we need to go county by county and ZIP code by ZIP code, offering specific, localized solutions.”
Schools can help. As trusted community-based institutions, schools are filled with teachers, special educators, social workers and office staff who are well equipped to listen empathetically and address delicate matters like misinformation, complacency, fear and distrust of science that feed vaccine hesitancy.
At our school in Brooklyn, we have created a campaign to understand and address hesitancy. Through town halls and outreach, we are creating safe spaces to hear about concerns. Our teachers and students are digging into the science, data and history of the pandemic and vaccine development. We’re using social media and newsletters to provide easy-to-understand information, translated into multiple languages. We are preparing to set up v
• Nausea
The incidence or the nature of side effects in cancer patients and survivors had been reported to be similar to with the general population.
Some people (16%) might develop swelling or pain under the vaccinated arm. This is often a normal response by the body’s immune system to the vaccine. A swollen lymph node under the arm might cause concern since this can also be a sign of breast cancer spread.
Oncologists recommend that patients with breast cancer or a history of breast cancer get the vaccine in the arm on the unaffected side.
5) Are there any exceptions for COVID-19 vaccination among cancer patients?
MaaT Pharma Announces Publication of Results from Completed Phase 1/2 ODYSSEE Clinical Trial in Nature Communications
MaaT011 was safe after induction chemotherapy in acute myeloid leukemia patients
MaaT011 formed the basis of the company s full ecosystem therapeutic approach that was continued with product candidatesMaaT013 (in acute graft-vs-host disease) and MaaT033 (in acute myeloid leukemia) MaaT Pharma announced today that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal,
Nature Communications. The data
demonstrated that the company s initial product candidate, MaaT011, an autologous fecal microbiota transfer treatment, was safe and effective in fully restoring the gut microbiota in the 20 per-protocol analyses set of acute myeloid leukemia (AML) patients. In addition, the MaaT011 treatment showed short- and long-term signs of positive clinical outcomes including the reduction of both intestinal inflammation and gut carriage